Antibody Production Shared Resource

抗体生产共享资源

• 批准号: 9248548
• 负责人: ROBERT H CARNAHAN
• 金额: $ 6.23万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9248548
• 关键词: Antibody; Production; Shared; Resource

BASIC RESEARCH GROUP CORE 003 – ANTIBODY PRODUCTION SHARED RESOURCE PROJECT SUMMARY/ABSTRACT Over the past two decades the view of monoclonal antibody utility has grown from valuable scientific reagents to include exciting and potent therapeutics. Over thirty monoclonal antibody–based therapies are now approved for human use in the U.S. and Europe, with nearly one-half of these therapeutics directed at cancer- relevant targets. In cancer research, the value of high-quality antibody reagents is impossible to overstate. A preponderance of molecular assays partially or completely depend upon the function of highly specific antibodies. Though there has been an explosion of commercially available antibodies, considerable variability remains in the actual specificity and utility of many of these reagents. Moreover, as research continues to progress, increasingly more challenging antibody needs continue to emerge (modification-specific antibodies, conformation- and isoform-specific antibodies, functional neutralizing or activating antibodies, etc.). For these reasons, the Vanderbilt-Ingram Cancer Center (VICC) has continuously maintained and supported a vibrant antibody development infrastructure. The Antibody Production Shared Resource (APSR) provides a full range of services supporting all manner of antibody-related projects (polyclonals, monoclonals, recombinant antibodies and antibody engineering, etc.). In addition to making antibodies, the APSR has continued to expand its suite of protein production services to include both antigens and customized functional recombinant proteins (e.g., growth factors, cytokines, etc.). This service is very cost efficient, has opened yet more tools for VICC researchers to obtain valuable reagents and has already successfully delivered critical recombinant proteins at a fraction of the commercial price. This robust suite of protein production and purification capabilities, along with our hybridoma services, provides unique capabilities for the VICC investigators. The proposed additions of in-house rabbit monoclonal antibody development, antibody humanization, and offering an expanded antibody and protein reagent catalog will further add to the technological and economic benefits this facility offers to VICC researchers.

基础研究组 CORE 003 – 抗体生产共享资源 项目概要/摘要 在过去的二十年里，单克隆抗体实用性的观点已经从有价值的科学试剂发展而来 包括令人兴奋和有效的治疗方法。目前已有三十多种基于单克隆抗体的疗法 在美国和欧洲批准用于人类，其中近一半的疗法针对癌症 - 相关目标。在癌症研究中，高质量抗体试剂的价值怎么强调都不为过。一个 分子检测的优势部分或完全取决于高度特异性的功能 抗体。尽管市售抗体呈爆炸式增长，但变异性相当大 仍然存在许多这些试剂的实际特异性和实用性。此外，随着研究的不断深入 随着进展，越来越具有挑战性的抗体需求不断出现（修饰特异性抗体， 构象和亚型特异性抗体、功能性中和或激活抗体等）。对于这些 由于这些原因，范德比尔特-英格拉姆癌症中心 (VICC) 不断维持和支持充满活力的 抗体开发基础设施。抗体生产共享资源（APSR）提供全方位 支持各种抗体相关项目（多克隆、单克隆、重组 抗体和抗体工程等）。除了制造抗体外，APSR 还继续 扩展其蛋白质生产服务套件，包括抗原和定制的功能重组 蛋白质（例如生长因子、细胞因子等）。这项服务非常具有成本效益，并且还开放了更多工具 VICC 研究人员获得了宝贵的试剂并已经成功交付了关键的重组体 蛋白质的价格仅为商业价格的一小部分。这套强大的蛋白质生产和纯化套件 能力以及我们的杂交瘤服务为 VICC 研究人员提供了独特的能力。这 提议增加内部兔单克隆抗体开发、抗体人源化和产品供应 扩大抗体和蛋白质试剂目录将进一步增加技术和经济效益 该设施为 VICC 研究人员提供。